SIGNAL completes enrollment in cohort A

9885 0

vaccinex_logoVaccinex Inc. completed enrollment of cohort A in its SIGNAL Clinical Trial, a randomized Phase 2 study to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 in subjects at risk for or with early signs of Huntington’s Disease. Read the press release.

Related Post

Seeking Survey Participants

April 3, 2017 0
If you are someone with HD, or a family member, friend or caregiver of a person living with HD, please…